Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

January 6, 2022 by Alan Khadavi

New Eosinophilic Esophagitis Treatments

New Eosinophilic esophagitis treatments are currently being studied. As of today, there are no eosinophilic esophagitis treatments that are FDA approved. On the horizon isĀ Eohilia Budesonide Oral Suspension for Eosinophilic Esophagitis. Plus there are many other ways that EoE can be treated, but there are no official medications yet. Here we will discuss new eosinophilic esophagitis treatments under investigation.

Eosinophilic Esophagitis (EoE) Treatment

Eosinophilic Esophagitis Diet

Eosinophilic Esophagitis (EoE) seems like the perfect fit for biologic medications, especially the ones that target IL-5. However, previous trials have not been very promising.

Xolair– Xolair was studied for EoE, unfortunately its data was not very impressive. It did not exhibit any reduction in eosinophil counts on repeat biopsy and only lead to mild improvement in symptom and quality of life scores.

Dupilumab-Dupixent was evaluated in phase 2 trials for EoE. It lead to a reduction in eosinophil levels and improvement in symptom and quality of life scores. It was dosed as 300mg weekly. Phase 3 data look promising.

Lirentelimab-Lirentelimab is a siglec-8 inhibitor being evaluated for EoE. Siglec-8 is expressed on mast cells, eosinophils, and basophils, and when targeted, it leads to destruction of eosninophils and prevent the release of stored and newly formed mediators of mast cells. This in turn leads to the decrease recruitment of local eosinophils. Studies showed a modest improvement in symptom and quality of life scores.

Nucala, Cinqair and Fasenra – All 3 IL-5 blockers are currently being studied as potential new treatments for eosinophilic esophagitis. All 3 lead to an expected reduction in tissue eosinophil levels. Improvement in symptoms and quality of life scores was seen.

Fasenra for Eosinophilic Esophagitis (EoE)

New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma

Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil)

Dectrekumab (intravenous) and RPC4046 are 2 new anti-IL-13 agents currently being studied for use in EoE. Both lead to a reduction in tissue eosinophil counts.

Anti-IL-15 and anti-tumor necrosis factor alpha are 2 other classes of agents being explored for EoE.

It remains to be seen if any of these agents will pass clinical trials and be recommended for EoE in the future.

Filed Under: Allergy Medicine, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

May 24, 2022

Lirentelimab study for Chronic Urticaria (Hives)

lirentelimab

May 24, 2022

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

dupixent for eoe

April 30, 2022

What are the best foods for Asthma?

best foods for asthma

April 26, 2022

Best Nasal Polyps Treatment

best nasal polyps treatment

April 19, 2022

Fasenra for Nasal Polyps, a new treatment option

fasenra for nasal polyps

April 19, 2022

Asivatrep a new topical treatment for Eczema

asivatrep cream

April 3, 2022

Kiwi Allergy can come in many flavors

Kiwi allergy

March 15, 2022

Ana o 3 IgE in diagnosing Cashew Nut Allergy

Ana o 3

March 13, 2022

Does Expired Albuterol work?

expired albuterol

March 8, 2022

Itepekimab in Asthma and COPD

itepekimab for asthma

Read More Posts...

Follow Us…

© 2022 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page